BioLineRx Ltd. (TLV:BLRX)

BioLineRx Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	21.99	4.8	-	-	-	-
Cost of Revenue	6.87	3.69	-	-	-	-
Gross Profit	15.13	1.11	-	-	-	-
Selling, General & Admin	32.58	31.58	11.53	5.31	4.75	4.67
Research & Development	10.39	12.52	17.63	19.47	18.17	23.44
Operating Expenses	42.97	44.1	29.16	24.78	22.93	28.11
Operating Income	-27.85	-42.99	-29.16	-24.78	-22.93	-28.11
Interest Expense	-3.68	-2.14	-1.79	-0.98	-1.47	-2.25
Interest & Investment Income	2.25	2.01	0.69	0.28	0.24	0.78
Currency Exchange Gain (Loss)	0.06	0.06	-0.35	0.28	-0.14	-
Other Non Operating Income (Expenses)	16	-10.84	5.64	-1.85	-5.72	4.14
EBT Excluding Unusual Items	-13.22	-53.91	-24.95	-27.05	-30.02	-25.45
Asset Writedown	-6.7	-6.7	-	-	-	-
Pretax Income	-19.92	-60.61	-24.95	-27.05	-30.02	-25.45
Net Income	-19.92	-60.61	-24.95	-27.05	-30.02	-25.45
Net Income to Common	-19.92	-60.61	-24.95	-27.05	-30.02	-25.45
Shares Outstanding (Basic)	1,141	963	774	663	253	146
Shares Outstanding (Diluted)	1,141	963	774	663	253	146
Shares Change (YoY)	23.34%	24.47%	16.75%	162.19%	72.70%	34.82%
EPS (Basic)	-0.02	-0.06	-0.03	-0.04	-0.12	-0.17
EPS (Diluted)	-0.02	-0.06	-0.03	-0.04	-0.12	-0.17
Free Cash Flow	-30.35	-22.72	-26.37	-23.67	-23.21	-22.73
Free Cash Flow Per Share	-0.03	-0.02	-0.03	-0.04	-0.09	-0.15
Gross Margin	68.78%	23.08%	-	-	-	-
Operating Margin	-126.62%	-895.65%	-	-	-	-
Profit Margin	-90.57%	-1262.79%	-	-	-	-
Free Cash Flow Margin	-138.00%	-473.42%	-	-	-	-
EBITDA	-25.49	-42.17	-28.5	-24.07	-21.99	-27.17
D&A For EBITDA	2.35	0.82	0.65	0.7	0.93	0.94
EBIT	-27.85	-42.99	-29.16	-24.78	-22.93	-28.11

Updated Nov 25, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.